Edition:
United States

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

1.51USD
26 May 2017
Change (% chg)

-- (--)
Prev Close
$1.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
189,971
52-wk High
$3.38
52-wk Low
$0.74

Latest Key Developments (Source: Significant Developments)

Biocept reports Q1 loss per share $0.21
Thursday, 11 May 2017 04:05pm EDT 

May 11 (Reuters) - Biocept Inc :Biocept reports first quarter 2017 financial results.Q1 loss per share $0.21.Q1 revenue $1.68 million versus $221,000.Biocept inc- cash and cash equivalents were $14.0 million as of March 31, 2017, compared with $4.6 million as of December 31, 2016.  Full Article

Biocept announces collaboration with the OHSU Knight Cancer Institute
Monday, 3 Apr 2017 08:05am EDT 

Biocept Inc : Biocept announces collaboration with the OHSU Knight Cancer Institute to increase clinical adoption of liquid biopsy testing and to co-develop additional assay platform capabilities . Biocept Inc - financial terms were not disclosed . Biocept Inc - agreement grants OHSU rights to commercially offer co's target selector liquid biopsy testing services exclusively throughout Oregon .Biocept Inc - Biocept and OHSU also plan to co-develop additional liquid biopsy assay technologies and platform capabilities.  Full Article

Biocept Q4 loss per share $0.27
Tuesday, 7 Mar 2017 04:05pm EST 

Biocept Inc : Biocept reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.27 .Q4 revenue $1.3 million versus $218,000.  Full Article

Biocept's CEO issues letter to stockholders
Thursday, 9 Feb 2017 08:05am EST 

Biocept Inc : Biocept's CEO issues letter to stockholders .Biocept- Later in year, plan to initiate commercial pilot program for hospital-based pathologists to interpret results of co's liquid biopsy tests locally.  Full Article

Biocept reports pricing of $10 million public offering of common stock and warrants
Friday, 14 Oct 2016 08:05am EDT 

Biocept Inc :Biocept Inc - pricing of an underwritten public offering of 9.1 million shares of its common stock and warrants at a combined offering price of $1.10.  Full Article

Biocept says board approved reverse stock split at ratio of 1:3
Thursday, 29 Sep 2016 09:21am EDT 

Biocept Inc : Proposal to amend co's certificate of amendment of certificate of incorporation approved by stockholders at special meeting - SEC filing . Amendment to increase authorized number of shares of company's common stock from 40 million to 150 million shares .Board approved a reverse stock split of company's common stock at a ratio of 1:3.  Full Article

Biocept reports agreement with Teneovita Medical
Tuesday, 30 Aug 2016 08:05am EDT 

Biocept Inc: Biocept announces agreement with Teneovita Medical to market and distribute its Liquid Biopsy testing platform in Canada .Preferred provider agreement with Teneovita Medical, a division of Teneovita Medical Innovations Inc..  Full Article

Biocept files for common stock offering of up to $10 mln
Friday, 12 Aug 2016 06:18pm EDT 

Biocept Inc :Files for common stock offering of up to $10 million - SEC Filing.  Full Article

Biocept expands distribution of liquid biopsy tests to Philippines
Thursday, 11 Aug 2016 08:05am EDT 

Biocept Inc : Biocept expands distribution of liquid biopsy tests to the Philippines . Additional terms of transaction were not disclosed . All diagnostic testing services under agreement will be performed in Biocept's San Diego-based CLIA-certified laboratory . Enters into agreement with Harlephil Ventures .Harlephil Ventures, Inc to have responsibility for sales, marketing, distribution, and reimbursement of company's liquid biopsy platform.  Full Article

Biocept Q2 loss per share $0.20
Tuesday, 2 Aug 2016 08:05am EDT 

Biocept Inc : Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.20.  Full Article

More From Around the Web

BRIEF-Biocept awarded U.S. Patent with broad claims for antibody capture of targets of interest on any solid surface

* Biocept awarded U.S. Patent with broad claims for antibody capture of targets of interest on any solid surface including CTCS and other materials shed by solid tumors into blood Source text for Eikon: Further company coverage: